Eli Lilly’s Oral GLP-1 Drug Orforglipron Shows Strong Results in Phase 3 Trial Eli Lilly’s investigational oral GLP-1 receptor agonist,…
Browsing: Clinical Updates
Atmo Biosciences has taken a major step toward commercializing its ingestible gas-sensing capsule after RMIT University officially transferred all intellectual…
This white paper by EndoSound provides a practical roadmap for integrating Endoscopic Ultrasound (EUS) into Ambulatory Surgery Centers (ASCs), traditionally…
Surgery for ulcerative colitis (UC) is often curative for colorectal disease and significantly improves quality of life, especially in patients…
New treatments for stage 4 colorectal cancer are significantly improving outcomes. While the liver is the most common site of…
Biotech leaders Guardant Health, Natera, and Exact Sciences are driving a major shift in cancer care through minimal residual disease…
A recent study at City of Hope found that adding circulating tumor DNA (ctDNA) testing to standard imaging surveillance for…
At the 2025 Society of Surgical Oncology (SSO) Annual Meeting, Dr. Thinzar Min Lwin of City of Hope highlighted two…
GLP-1 receptor agonists, originally developed for type 2 diabetes, are now transforming care across multiple conditions—including obesity, cardiovascular disease, neurodegenerative…
The first quarter of 2025 brought significant advances in gastroenterology, including FDA approvals for mirikizumab and guselkumab, expanding treatment options…